181 related articles for article (PubMed ID: 32741080)
1. Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
Wood ME; McKinnon W; Garber J
Breast J; 2020 Aug; 26(8):1528-1534. PubMed ID: 32741080
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
6. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
7. Screening for familial cancer risk: Focus on breast cancer.
Rousset-Jablonski C; Gompel A
Maturitas; 2017 Nov; 105():69-77. PubMed ID: 28818315
[TBL] [Abstract][Full Text] [Related]
8. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
[TBL] [Abstract][Full Text] [Related]
9. Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.
Hudson L; Gower N; Lenarcic S; Trufan SJ; White RL
Ann Surg Oncol; 2020 Jul; 27(7):2248-2254. PubMed ID: 31974710
[TBL] [Abstract][Full Text] [Related]
10. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Angeli D; Salvi S; Tedaldi G
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046255
[TBL] [Abstract][Full Text] [Related]
11. Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA.
Piombino C; Cortesi L; Lambertini M; Punie K; Grandi G; Toss A
J Oncol; 2020; 2020():6384190. PubMed ID: 32733558
[TBL] [Abstract][Full Text] [Related]
12. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
13. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM
BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479
[TBL] [Abstract][Full Text] [Related]
14. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
15. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
[TBL] [Abstract][Full Text] [Related]
16. Hereditary genes and SNPs associated with breast cancer.
Mahdi KM; Nassiri MR; Nasiri K
Asian Pac J Cancer Prev; 2013; 14(6):3403-9. PubMed ID: 23886119
[TBL] [Abstract][Full Text] [Related]
17. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer and ovarian cancer genetics.
Edlich RF; Winters KL; Lin KY
J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
[TBL] [Abstract][Full Text] [Related]
19. Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing.
Rosenthal ET; Evans B; Kidd J; Brown K; Gorringe H; van Orman M; Manley S
J Am Coll Radiol; 2017 Apr; 14(4):561-568. PubMed ID: 28011157
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]